MCI-196

DRUG6 trials

Sponsors

Tanabe Pharma Corporation

Conditions

Chronic Kidney DiseaseDialysisDyslipidemiaHyperphosphatemiaType 2 Diabetes

Phase 2

Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

CompletedNCT00497198

Tanabe Pharma CorporationType 2 Diabetes

Start: 2005-10-31End: 2007-09-30Updated: 2026-01-06

Phase 3

A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia

CompletedNCT00506441

Tanabe Pharma CorporationChronic Kidney Disease, Dialysis, Hyperphosphatemia

Start: 2007-09-30End: 2009-09-30Updated: 2026-01-08

A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia

CompletedNCT00542386

Tanabe Pharma CorporationChronic Kidney Disease, Dialysis, Dyslipidemia +1

Start: 2007-12-31End: 2009-11-30Updated: 2026-01-08

A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

CompletedNCT00542815

Tanabe Pharma CorporationChronic Kidney Disease, Dialysis, Hyperphosphatemia

Start: 2007-11-30End: 2010-08-31Updated: 2026-01-07

Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia

CompletedNCT00772382

Tanabe Pharma CorporationChronic Kidney Disease, Dialysis, Hyperphosphatemia

Start: 2008-12-31End: 2010-08-31Updated: 2026-01-08

Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis

CompletedNCT00858637

Tanabe Pharma CorporationChronic Kidney Disease

Start: 2009-03-31End: 2010-03-31Updated: 2026-01-07